Drug Delivery to the Brain

Part I-Physiology and Basic Principles of Drug Handling for the CNS.- Anatomy and Physiology of the Blood Brain Barriers.- Drug Delivery to the Brain: Integrating Neuroscience, Physiology, and Brain Barriers Science.- Brain Delivery of Therapeutics via Transcytosis: Types and Mechanisms of Vesicle-Mediated Transport Across the BBB.- Brain- Arachnoid Barrier as an Important Clearance Pathway from CSF.- BBB Pharmacoproteomics: Quantitative Targeted Absolute Proteomics (QTAP): Species Differences.- Drug Metabolism at the BBB and the BCFSB.-  PART II-PK Concepts and Methods for Studying CNS Drug Delivery.- Pharmacokinetics Concepts in Brain Drug Delivery.-  In Vitro Models of CNS Barriers.- Human In Vitro BBB Models Derived from Pluripotent Stem Cells.- In situ and In vivo Animal Models.- Principles of PET and Its Role in Understanding Drug Delivery to the Brain.- Prediction of CNS PK and PD Using Translational Research Approaches.- Part III-Industrial Approachesfor Investigation of Potential CNS Drugs.- Drug Discovery Methods for Studying Brain Drug Delivery and Distribution.- Prediction of Drug Exposure in the Brain From the Chemical Structure.- Integrated Approach to Optimizing CNS Penetration in Drug Discovery.- Part IV: Strategies for Improved CNS Drug Delivery.- Intranasal Drug Delivery to the Brain.- Blood to Brain Drug Delivery Using Nanocarriers.- Enhancing CNS Exposure Through Brain Endothelial Cell RMT-Exploiting the Transferrin Receptor at the BBB.- Therapeutic Osmotic Modification of the BBB in the Treatment of CNS Pathologies.-  Biophysical Perspectives on BBB Permeability Enhancement by Ultrasound and Microbubbles for Targeted Drug Delivery in the Clinical Setting.- Optimization of Blood Brain Barrier Opening With Focused Ultrasound-The Animal Perspective.-  CNS Gene Therapy Using Adeno-Associated Virus (AAV) Vectors .- Part V-CNS Drug Delivery in Disease Conditions.- Disease Influence on BBB

Elizabeth C.M. de Lange (PhD) is Head of the Target Site Equilibration Group at the Division of Pharmacology of the Leiden Academic Center for Drug Research (LACDR). Her research program focuses on the development of generally applicable predictive PKPD models on CNS drugs using advanced in vivo animal models and mathematical modeling techniques, with a number of recent successes. She is an Editorial Board member of the journal Fluids and Barriers of the CNS, and an Editorial Advisory Board member of the Journal of Pharmaceutical Sciences and of Pharmaceutical Research. She has been the cofounder and (co-)Chair at the 1st, 2nd and 5th International Symposia on Microdialysis, and has been the Chair of the 9th International Conference on Cerebral Vascular Biology (2011). Among many other functions within the American Association of Pharmaceutical Scientists, she is the 2014 Chair of theAnnual Meeting Programming Committee. With her company "In Focus" she provides courses, training and advice on microdialysis, pharmacokinetics, BBB transport, intra-brain distribution and PKPD relationships.

Margareta Hammarlund-Udenaes (PhD) is a Professor in Pharmacokinetics and Pharmacodynamics (PKPD) at Uppsala University and the Head of the Translational PKPD Group. Her research is focused at studying pharmacokinetic aspects of BBB transport of drugs in relation to CNS effects, which has led to the development of new concepts and methods within the BBB transport area, focusing on unbound drug relationships. Dr. Hammarlund-Udenaes is an Associate Editor of Pharmaceutical Research and a member of the Editorial Advisory Board of Journal of Pharmaceutical Sciences and Fluids and Barriers of the CNS. She became an American Association of Pharmaceutical Scientists' Fellow in 2005. She is a frequent lecturer at conferences and in drug industry. Her company gives courses and advice in PKPD and BBB transport issues. She co-founded